Equities

FUSN

CA36118A1003

Real-time Estimate Cboe BZX Other stock markets 14:15:53 2024-05-23 EDT			5-day change	1st Jan Change
21.53 ^USD	+0.05%		+0.23%	+123.83%

05-09	Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	CI
05-07	Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Fusion Pharmaceuticals Inc. agreed to acquire Exclusive Worldwide License for Actinium-Based PSMA Targeted Radiotherapy from Heidelberg University and Euratom represented by the European Commission, Joint Research Centre.

February 15, 2024

Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) agreed to acquire Exclusive Worldwide License for Actinium-Based PSMA Targeted Radiotherapy from Heidelberg University and Euratom represented by the European Commission, Joint Research Centre on February 16, 2024.

Latest news about FUSN PHAR

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	05-09	CI
Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
TD Cowen Downgrades Fusion Pharmaceuticals to Hold	04-16	MT
Fusion Pharmaceuticals Inc. Presents Interim Efficacy and Safety Data from the Phase 2 TATCIST Open-Label Clinical Trial Evaluating FPI-2265	04-09	CI
Fusion Pharmaceuticals Narrows Q4 Loss; Enters Sale Deal With AstraZeneca	03-20	MT
Fusion Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Fusion Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-20	CI
B. Riley Downgrades Fusion Pharmaceuticals to Neutral From Buy on Heels of Announced Sale to AstraZeneca, Adjusts PT to $23 From $13	03-20	MT
Bloom Burton Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21.50 From $20	03-20	MT
Fusion Pharmaceuticals Downgraded by RBC to Sector Perform From Outperform, Speculative Risk Removed, Price Target Raised to $21 From $16	03-20	MT
JonesTrading Downgrades Fusion Pharmaceuticals to Hold From Buy	03-20	MT
Sector Update: Health Care Stocks Rise Late Afternoon	03-19	MT
Jefferies Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21 From $10	03-19	MT
Morgan Stanley Downgrades Fusion Pharmaceuticals to Equalweight From Overweight, Raises Price Target to $21 From $10	03-19	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	03-19	MT
Sector Update: Health Care	03-19	MT
Top Midday Gainers	03-19	MT
Truist Securities Downgrades Fusion Pharmaceuticals to Hold From Buy, Adjusts Price Target to $21 From $11	03-19	MT
Top Stories at Midday: February US Housing Starts Rise; AstraZeneca to Acquire Fusion Pharmaceuticals; IFF to Sell Pharma Solutions Unit; Unilever to Spin Off Ice Cream Unit; MicroStrategy Completes Notes Offering; Super Micro Computer Files Shelf; Nvidia Unveils Latest GPU	03-19	MT
William Blair Downgrades Fusion Pharmaceuticals to Market Perform From Outperform	03-19	MT
Raymond James Downgrades Fusion Pharmaceuticals to Market Perform From Strong Buy, Raises Price Target to $21 From $16	03-19	MT
Brookline Capital Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21 From $20	03-19	MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	03-19	MT
Wedbush Downgrades Fusion Pharmaceuticals to Neutral From Outperform on Heels of Announced Sale to AstraZeneca, Adjusts PT to $24 From $13	03-19	MT
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	03-19	MT

Chart FUSN PHAR

Duration

Period

More charts

Company Profile

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. Its technology enables it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. The Company's lead product candidate is FPI-1434, that utilizes Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor I receptor (IGF-1R) with alpha emitting isotope actinium-225.

Sector

More about the company